Clinical trials
Completed Phase 1 Sleep Initiation and Maintenance Disorders trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
59 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2004 | 3 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 5 |
| 2008 | 4 |
| 2009 | 4 |
| 2010 | 9 |
| 2011 | 6 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2017 | 4 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 59 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 7 |
| Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | 6 |
| Eisai Inc. | 5 |
| GlaxoSmithKline | 4 |
| Eli Lilly and Company | 3 |
| Sunshine Lake Pharma Co., Ltd. | 2 |
| Beth Israel Deaconess Medical Center | 1 |
| Boston University | 1 |
| Centre hospitalier de l'Université de Montréal (CHUM) | 1 |
| Coeruleus Ltd. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sleep Initiation and Maintenance Disorders | 59 |
| Parasomnias | 2 |
| Parkinson Disease | 2 |
| Sleep Deprivation | 2 |
| Sleep Wake Disorders | 2 |
| Anxiety Disorders | 1 |
| Autistic Disorder | 1 |
| Brain Concussion | 1 |
| Breast Neoplasms | 1 |
| Chronic Pain | 1 |
Trials
Showing 1 to 25 of 59. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.